Inactive Instrument

Anchiano Therapeutics Ltd.

Equities

ANCN

US03280X1028

Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 06, 2019 at 06:45 pm IST

Anchiano Therapeutics Ltd. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced net loss was USD 1.810 million compared to USD 5.298 million a year ago. For the half year, net loss was USD 20.257 million compared to USD 8.837 million a year ago.

Latest news about Anchiano Therapeutics Ltd.

DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus	16/21/16	MT
Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger	16/21/16	MT
Anchiano Therapeutics Ltd.(NasdaqCM:ANCN) dropped from NASDAQ Composite Index	16/21/16	CI
ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. in a reverse merger transaction.	16/21/16	CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	10/21/10	CI
Anchiano Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt	09/21/09	CI
Anchiano Therapeutics : Chemomab Plan Merger to Advance Treatment for Fibrosis-Related Diseases	15/20/15	MT
Anchiano Therapeutics Ltd. and Chemomab Ltd. Announce Executive Appointments	15/20/15	CI
ChemomAb Ltd. entered into letter of intent to acquire Anchiano Therapeutics Ltd. for for $27.2 million in a reverse merger transaction.	15/20/15	CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/20/16	CI
Anchiano Therapeutics Ltd Appoints Neil Cohen as Chief Executive Officer	21/20/21	CI
Anchiano Therapeutics Ltd Appoints Andrew Fine as the Chief Financial Officer	21/20/21	CI
Anchiano Therapeutics Ltd Announces Board Changes	21/20/21	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020	14/20/14	CI
Anchiano Therapeutics Ltd Announces Resignation of Frank Haluska as CEO	10/20/10	CI
Anchiano Therapeutics Ltd Announces Executive Changes	10/20/10	CI
Frank Haluska to Resign as Director of Anchiano Therapeutics Ltd	10/20/10	CI
Anchiano Appoints Stan Polovets as Chairman of the Board	26/20/26	CI
Anchiano Therapeutics Ltd Announces Board Changes	22/20/22	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020	08/20/08	CI
Anchiano Therapeutics Ltd Announces Executive Changes	06/20/06	CI
Anchiano Therapeutics Ltd Announces Board Elections	25/20/25	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2019	18/20/18	CI
Anchiano Therapeutics Ltd Auditor Raises 'Going Concern' Doubt	17/20/17	CI
Anchiano Therapeutics Ltd Announces Resignation of Efrat Makov from Board of Directors	10/20/10	CI

Chart Anchiano Therapeutics Ltd.

Duration

Period

More charts

Company Profile

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Sector

More about the company